The product license allows finished product manufacturers to make specific recommendations based on the published scientific data presented to Health Canada. ThymoQuin, as an oral supplement (capsule or soft gel), can be used to:
- Help support healthy liver function*
- Help support cardiovascular health*
- Help support healthy glucose levels*
- Help support stress relief*
- Help moderate general feeling of stress*
- Help support healthy gut microbiota*
“It comes with great pleasure to announce that our patented black seed oil now has the backing of these structure-function claims for Canadian brand manufacturers,” said Morris Zelkah, CEO of TriNutra. “We are continually pushing for natural product education and ingredient differentiation through our unique growing conditions, proprietary processing, and ongoing research to ensure a more potent, stable, bioavailable and efficacious product for the end consumer.”
ThymoQuin is only patented, USP-grade, full-spectrum, cold-pressed black seed oil standardized to 3% thymoquinone and very low (<1.25%) free fatty acids. It is clinically tested to support a balanced inflammatory response, improve mitochondrial activity, including ATP production, and deliver excellent antioxidant activity and antimicrobial effects.
The announcement comes on the heels of its recently granted United States patent for TriNutra’s black seed oil composition.
To learn more about ThymoQuin® visit: TriNutra.com
*These statements have not been evaluated by the Food and Drug Administration. This ingredient is not intended to diagnose, treat, cure or prevent any disease. This material is educational in nature and is not intended to serve as regulatory and/or legal advice.
